Literature DB >> 8770438

Plasma beta-endorphin concentrations in people with learning disability and self-injurious and/or autistic behaviour.

S H Willemsen-Swinkels1, J K Buitelaar, F G Weijnen, J H Thijssen, H Van Engeland.   

Abstract

BACKGROUND: It has been suggested that the key variable in reduced plasma immunoreactive beta-endorphin concentrations in autistic subjects may be concomitant self-injurious behaviour.
METHOD: We studied morning levels of plasma beta-endorphin in 33 learning disabled people with self-injurious and/or autistic behaviour.
RESULTS: The beta-endorphin level of the subjects with severe self-injurious behaviour proved to be significantly lower than of autistic subjects without severe self-injurious behaviour (3.6 (1.4) pmol/l v. 5.8 (4.3) pmol/l; t-test: P = 0.045. Replication: 3.7 (1.1) pmol/l v. 5.7 (3.8) pmol/l; t-test: P = 0.043). Individuals with mild and occasional self-injurious behaviour were found to have beta-endorphin levels comparable to those without self-injurious behaviour. Further, subjects being treated with neuroleptics and lower beta-endorphin levels than untreated subjects.
CONCLUSIONS: These results stress that in any study of opioid systems of learning disabled people, it is very important to differentiate between people with and without severe self-injurious behaviour. The results support the idea that severe self-injurious behaviour may be related to functional disturbances in the endogenous opioid system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770438     DOI: 10.1192/bjp.168.1.105

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  5 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

Review 3.  Medication treatment in subjects with autistic spectrum disorders.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

4.  Naltrexone treatment reverses astrocyte atrophy and immune dysfunction in self-harming macaques.

Authors:  Kim M Lee; Kevin B Chiu; Peter J Didier; Kate C Baker; Andrew G MacLean
Journal:  Brain Behav Immun       Date:  2015-07-17       Impact factor: 7.217

Review 5.  What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients.

Authors:  Angelo G I Maremmani; Matteo Pacini; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2019-02-03       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.